Enki™ is designed to make generating novel molecule structures easy. Expand your imagination in 4 easy steps
No data required. Just define your TPP and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results.
Define your TPP
Select your on-target(s), off-target(s), and other properties in minutes.
The Enki™ Platform is the first commercially accessible foundation model for small molecules. Fixed transaction pricing. No milestones. No royalties.
Company
Founded in September 2019, we are a team of experienced AI/machine learning researchers and medicinal and computational chemists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to redefine the unit economics of drug discovery and development.
Our Team
We are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.
Board, Observers, and Advisors
Funding, Partners & Investors
Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.
In the Press
Recent News & Events
Variational AI Files Two US Provisional Patents for Potential COVID-19 Drug Created by Generative AI
Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics of drug development, today announced that the company has filed two provisional patents with the United States Patent...
Variational AI Adds Jennifer Hamilton as Advisor
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leader Jennifer Hamilton, Ph.D. as a company advisor.
Variational AI Adds Leading Oncology Researchers to Scientific Advisory Board
Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leaders Dr. John F. Boylan and Dr. Mads Daugaard to the company’s Scientific Advisory Board.
Variational AI is hiring!
Please see open job listing below or contact us if you would like to join the team in the area of machine learning, computational medicinal chemistry, and business development.
